ClinicalTrials.gg
RecruitingNCT06224140HepFreeHDUpdated Oct 26, 2024

Heparin-Free Chronic HemoDialysis Assessment

An interventional study of Heparin Anticoagulation and Regional Anticoagulation Procedure (RAP) in End-Stage Renal Disease, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.

Planned enrollment
47th of 105
100 · median 70
Started
2024
with 9 others
No phase
55 of 145
10 open now
Primary completion
2026-09
later than 9 of 32 live
Registered
134th of 145
by date
Lead sponsor
4 of 145
Assistance Publique Hopitaux De Marseille

Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 47th largest by planned enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2024, is one of 55 with no phase, reaches primary completion later than 9 of the 32 other live ones, and was the 134th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Kidney Failure, Chronic with a site in France, or all of them as a file.
02

Study summary

Intermittent hemodialysis is a complex technique which requires careful monitoring of anticoagulation levels to prevent clotting and reduce the risk of bleeding complications. Dialysis patients often exhibit hypercoagulable tendencies due to uremic state, turbulent blood flows in dialysis procedures, and thrombogenic exposure to artificial surfaces of dialysis tubing. Patients with ESRD may experience both dialyzer clotting and excessive bleeding, so individualized heparin dosing and periodic adjustments are necessary to ensure adequate anticoagulation during hemodialysis. The ideal anticoagulant should prevent thrombosis while minimizing the risk of intra- and interdialytic bleeding. The use of heparin carries risks such as worsening of osteoporosis and dyslipidemia, allergic reactions like pruritus, and the potential for life-threatening heparin-induced thrombocytopenia (HIT) for which avoidance of heparin is necessary during dialysis.Heparin, in both its unfractionated heparin (UFH) and low molecular weight heparin (LMWH) forms, is the most commonly used anticoagulant, though evidence comparing their efficacy and risk of bleeding remains inconclusive. End-stage renal disease (ESRD) patients, who are already at higher risk of serious bleeding, may benefit from regional anticoagulation (RA) techniques, as they typically receive around 600,000 IU of heparin per year. The investigators performed routinely a simplified regional anticoagulation procedure (RAP) using a constant calcium re-injection rate over the time to avoid hypocalcemia. This procedure eliminates the need for citrate infusion and calcium monitoring, and reduces nurse workload in a chronic dialysis unit. The investigators compared 21 chronic dialysis patients with 198 RA and 195 heparin sessions, where each patient acted as their own control. None of them were on VKA during the RA sessions, 62% were on single anti-platelet therapy and 14% were on dual anti-platelet therapy. The dialysis session success rate was 94% in the RA group and 97% in the heparin group, with no significant differences (p=0.22). The circuit loss rate was 1.5% per RA session and 0.5% per heparin session (p=0.23), and the early blood restitution rate was 3% and 1.5% (p=0.50) in the RA and heparin groups, respectively

Hypothesis: RAP can be as effective as systemic anticoagulation with heparin for intermittent dialysis in chronic hemodialysis patients, with the potential to reduce the rate of hemorrhagic events

03

Conditions studied

  • End-Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman aged 18 years or more
  • Patients with end-stage renal disease (ESRD) under intermittent hemodialysis, for more than 3 months prior to screening and with a dialysis duration prescription of at least 4 hours
  • Effective anticoagulation either by UFH or by LMWH of the dialysis session defined by the absence of circuit loss in the last 3 months.
  • Dialysis adequacy defined by a mean Kt/V ≥1.2.
  • Calcemia within the normal range at inclusion (2.2 to 2.6 mmol/L) (based on the results of the last monthly blood test)
  • Subject affiliated to or beneficiary of a social security system.
  • Subject having signed written .

Exclusion criteria

Exclusion Criteria:

  • Dysfunctional vascular access at the screening
  • Unipunction of the AVF
  • Patient treated by hemofiltration or hemodiafiltration procedure
  • Current anticoagulation treatment
  • Patient treated by digitalizing drugs
  • Patient treated by thiazide diuretics
  • Patient with hypercalcemia and/or hypercalciuria
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Active hemorrhage
  • High bleeding risk defined by the following situations: recent bleeding of less than 7 days, recent post-operative period of less than 7 days, recent head trauma of less than 7 days, recent ischemic stroke of less than 7 days, uremic pericarditis.
  • Body weight \< 45 kg and > 140 kg at screening.
  • Known allergy to citrate
  • Hospitalization at the screening for all other causes apart from dialysis
  • Moribund status (defined by the expectation of death in less than three months).
  • Liver failure (to prevent citrate liver toxicity) based on the results of the last monthly or quarterly blood test
  • Ongoing participation in a concurrent interventional study in dialysis or with anti-coagulation therapy
  • Pregnancy (declarative) or breastfeeding and all the other categories of people with special protection according to the French Code de la Santé Publique (CSP): patients under legal supervision, patients hospitalized without consent, patients admitted in social or sanitary structures for care and not research, and patients in emergency situations
  • Patients unable to give an or unwilling to participate in the study.
  • Heparin-coated membrane in current dialysis prescription
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Heparin Anticoagulation

    Procedure: Heparin Anticoagulation

  • Experimental
    Regional Anticoagulation Procedure (RAP)

    Procedure: Regional Anticoagulation Procedure (RAP)

Interventions

  • ProcedureHeparin Anticoagulation

    Conventional dialysis with heparin as anticoagulant treatment

  • ProcedureRegional Anticoagulation Procedure (RAP)

    Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.

06

What researchers measure

Primary outcomes

  1. Demonstrate the non-inferiority of the regional anticoagulation procedure compared to heparin anticoagulation on the dialysis sessions success three times per week

    The primary endpoint will be the rate of dialysis sessions success over 6 months between two therapeutic strategies: * Regional anticoagulation procedure (RAP) * Heparin anticoagulation

    Time frame: 6 months

Secondary outcomes

  1. Compare between the groups clinical Impact at each dialyses session on bypass loss

    Rate of bypass loss

    Time frame: 6 months

  2. Compare between the groups clinical Impact at each dialyses session on early bypass restitution

    Rate of early bypass restitution (defined as a restitution 30 minutes or more before the end of the prescribed time)

    Time frame: 6 months

  3. Compare between the groups clinical Impact at each dialyses session on dialysis duration

    Mean difference of dialysis duration over 6 month between the groups

    Time frame: 6 months

  4. Compare between the groups clinical Impact at each dialyses session on fistula compression time extended more than 10 minutes

    Rate of fistula compression time extended more than 10 minutes after a dialysis session

    Time frame: 6 months

  5. Compare between the groups clinical Impact during the total duration of the study on incidence of hemorrhagic events

    Incidence rate of hemorrhagic events

    Time frame: 6 months

  6. Compare between the groups clinical Impact during the total duration of the study on dialysis adequacy

    Time average-dialysis adequacy difference defined by the average kt/v over 6 months

    Time frame: 6 months

  7. Compare between the groups clinical Impact during the total duration of the study on relative effects on phosphocalcic balance

    Mean difference at months +6 and time-average evolution over 6 month for calcium, phosphor, bone-specific alkaline phosphatase and parathyroid hormone concentration between the groups

    Time frame: 6 months

  8. Compare between the groups clinical Impact during the total duration of the study on incidence of Hyperparthyroidism

    Rate of hyperparathyroidism defined par PTH \> 9N at month +6

    Time frame: 6 months

  9. Compare between the groups clinical Impact during the total duration of the study on incidence of non-hemorrhagic heparin-related complications

    Rate of non-hemorrhagic heparin-related complications: 1. In the heparin group: heparin-induced thrombocytopenia, 2. Between the groups: hyperkalemia, hypertriglyceridemia, hypersensitivity reactions, pruritus at months +6

    Time frame: 6 months

  10. Compare between the groups clinical Impact during the total duration of the study on incidence of cardiovascular-related mortality and major cardiovascular events (MACE)

    Incidence rate of MACE at months +6

    Time frame: 6 months

  11. Compare between the groups clinical Impact during the total duration of the study on global mortality

    All-cause mortality rate at month +6

    Time frame: 6 months

  12. Compare between the groups the tolerance of per-dialytic hypotension

    Rate of per-dialytic hypotension over 6 months

    Time frame: 6 months

  13. Compare between the groups the tolerance of adverse events

    Rate of adverse events over 6 months

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2026, 26 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 26 months is above that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 25, 2024
StartActual
Jun 6, 2024
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06224140
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Jun 6, 2024
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Oct 26, 2024

Study contacts

Thomas Robert
Contact
thomas.robert@ap-hm.fr
04 91 38 41 17 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion